Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)
Keywords: NK1-receptor occupancy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: yes

Brief summary:
This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.

Detailed description:
The third arm of the study (Aprepitant 250 mg) will only be conducted if the real-time assessment of the NK1-receptor occupancy data between fosaprepitant 150 mg \& aprepitant 165 mg reveals that the primary hypothesis will not be supported.

Arms:
arm 1: Fosaprepitant 150 mg arm 2: Aprepitant 165 mg arm 3: Aprepitant 250 mg

Interventions: intervention 1: Fosaprepitant 150 mg intervention 2: Aprepitant 165 mg intervention 3: Aprepitant 250 mg intervention 4: Dexamethasone (12-8-16-16 mg) intervention 5: Dexamethasone (12-8-8-16 mg) intervention 6: Ondansetron intervention 7: MK0999
Intervention descriptions: intervention 1: a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal intervention 2: a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal intervention 3: a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal intervention 4: Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal. intervention 5: Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal. intervention 6: The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion intervention 7: I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)

Protocol document: